<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Biology and normal function of factor VIII and factor IX</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Biology and normal function of factor VIII and factor IX</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Biology and normal function of factor VIII and factor IX</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara A Konkle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemostasis is the process of blood clot formation at the site of vessel injury. This process begins with the formation of the platelet plug, followed by activation of the clotting cascade and propagation and stabilization of the clot (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>).</p><p>One of the major multicomponent complexes in the coagulation cascade is the intrinsic X-ase (ten-ase) complex. This complex consists of activated factor IX (factor IXa) as the protease, activated factor VIII (factor VIIIa), calcium, and phospholipids as the cofactors, and factor X as the substrate. Factor IXa can be generated by either factor XIa, activation of the intrinsic pathway, or by the tissue factor/factor VIIa complex. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Multicomponent complexes'</a>.)</p><p>The biology of factor VIII and factor IX is reviewed here. Deficiencies in either of these coagulation factors lead to hemophilia (hemophilia A and hemophilia B, respectively), which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">FACTOR VIII</span><span class="headingEndMark"> — </span>The <em>F8</em> gene is located on the X chromosome. It is one of the largest known genes, divided into 26 exons that span 186,000 base pairs [<a href="#rid1">1,2</a>]. Factor VIII is synthesized as a single chain polypeptide of 2351 amino acids. A 19-amino acid signal peptide is cleaved by a protease shortly after synthesis so that circulating plasma factor VIII is a heterodimer.</p><p>Factor VIII circulates in plasma in a noncovalent complex with von Willebrand factor. Cleavage of plasma factor VIII by thrombin or factor Xa at Arg372 and Arg1689 is necessary to activate factor VIII and allow it to participate in the intrinsic pathway X-ase [<a href="#rid3">3,4</a>]. Activated factor VIII (factor VIIIa) is inactivated by activated protein C in conjunction with protein S; the site of proteolytic inactivation is Arg336 in the A1 subunit [<a href="#rid3">3</a>]. Factor VIIIa is also cleaved by activated protein C at Arg562 in the A2 subunit.</p><p class="headingAnchor" id="H3"><span class="h2">Structure</span><span class="headingEndMark"> — </span>Factor VIII consists of a heavy chain with A1 and A2 domains (<a class="graphic graphic_figure graphicRef120087" href="/z/d/graphic/120087.html" rel="external">figure 2</a>); a connecting region with a B domain; and a light chain with A3, C1, and C2 domains [<a href="#rid5">5-8</a>]. The functions of factor VIII reflect binding at specific sites within the molecule:</p><p class="headingAnchor" id="H4"><span class="h3">C2 domain</span><span class="headingEndMark"> — </span>The C2 domain binds to the procoagulant phospholipid phosphatidylserine on activated platelets and endothelial cells [<a href="#rid9">9,10</a>] and to von Willebrand factor [<a href="#rid10">10,11</a>]. An overlap exists in the epitope for both binding functions [<a href="#rid10">10,11</a>]. A different site in the C2 domain appears to contain the binding site for factor Xa. In vitro, an antibody directed against this binding site prevents factor VIII activation by factor Xa [<a href="#rid12">12</a>]. A thrombin binding site also is present in the C2 domain that is responsible for factor VIII cleavage at Arg1689 [<a href="#rid13">13</a>].</p><p>The importance of the C2 domain is illustrated by observations in non-hemophilic patients with a bleeding tendency caused by acquired autoantibodies against factor VIII. In some of these patients, the antibodies are directed against the C2 domain and prevent interaction with phosphatidylserine [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">A2 domain</span><span class="headingEndMark"> — </span>The A2 domain is a site of factor IXa binding, the active enzyme in the X-ase pathway [<a href="#rid14">14-18</a>].</p><p class="headingAnchor" id="H6"><span class="h3">A1/A3-C1-C2 dimer</span><span class="headingEndMark"> — </span>The A1/A3-C1-C2 dimer also contributes to factor IXa binding [<a href="#rid17">17,18</a>], a part of which occurs within the A3 domain [<a href="#rid14">14,18</a>].</p><p class="headingAnchor" id="H7"><span class="h3">B domain</span><span class="headingEndMark"> — </span>The heavily glycosylated B domain displays no significant homology to any known protein. It serves as a connecting region that separates the second and the third A domains but is not required for clotting activity [<a href="#rid19">19</a>]. The B domain plays a role in intracellular quality control and factor VIII secretion and potentially regulatory roles in plasma during factor VIII activation, platelet binding, inactivation, and clearance [<a href="#rid20">20</a>].</p><p>Antibodies directed against these domains, occurring in patients with hemophilia or as an acquired disorder in patients without hemophilia, can lead to bleeding episodes or, in patients with hemophilia, bleeding that is more difficult to control. In some cases of acquired disease, for example, the antibodies are directed against the C2 domain and prevent interaction with phosphatidylserine [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1308.html" rel="external">"Inhibitors in hemophilia: Mechanisms, prevalence, diagnosis, and eradication"</a> and  <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)"</a>.)</p><p class="headingAnchor" id="H14758401"><span class="h2">Site of production</span><span class="headingEndMark"> — </span>The site of factor VIII production has been controversial, but studies using gene targeting have identified endothelial cells as the primary (and perhaps exclusive) source of factor VIII synthesis and secretion [<a href="#rid21">21,22</a>]. Endothelial cell knockout of the <em>F8</em> gene or the gene responsible for factor VIII secretion cause hemophilia in mice, whereas liver-specific knockout of either gene does not affect plasma factor VIII levels. (See  <a class="medical medical_review" href="/z/d/html/2894.html" rel="external">"Tools for genetics and genomics: Specially bred and genetically engineered mice", section on 'Knockout mice'</a>.)</p><p>Factor VIII production is thus different from all other coagulation factors, which are made by hepatocytes, and similar to von Willebrand factor, which is produced in endothelial cells. (See <a class="local">'Binding to von Willebrand factor'</a> below.)</p><p>Factor VIII was previously thought to be produced at least partially by the liver, based on observations from liver transplantation experiments in animals and clinical results in patients with hemophilia A who undergo liver transplantation for liver failure or hepatocellular carcinoma. Liver transplantation from an animal without hemophilia to a hemophilic animal partially corrected factor VIII deficiency in the recipient, and liver transplantation from a hemophilic animal into a non-hemophilic animal partially depleted factor VIII in the recipient. The presence of a significant vascular bed in the transplanted liver likely explains this finding.</p><p class="headingAnchor" id="H8"><span class="h2">Binding to von Willebrand factor</span><span class="headingEndMark"> — </span>Factor VIII circulates in plasma in a noncovalent complex with von Willebrand factor (VWF) (<a class="graphic graphic_figure graphicRef120087" href="/z/d/graphic/120087.html" rel="external">figure 2</a>). The interaction between factor VIII and VWF has two main effects:</p><p class="bulletIndent1"><span class="glyph">●</span>Binding to VWF protects factor VIII from proteolytic inactivation by activated protein C and its cofactor, protein S [<a href="#rid23">23-25</a>]. VWF slows the inactivation of factor VIII 10- to 20-fold [<a href="#rid24">24,25</a>]; this prolongs its half-life in the circulation fivefold [<a href="#rid23">23</a>]. It also modulates clearance of the VWF-factor VIII complex [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Binding to VWF is thought to concentrate factor VIII at sites of vascular injury and active hemostasis through the attachment of VWF to subendothelial matrix proteins and adherent platelets. (See  <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'VWF functions'</a>.) </p><p></p><p class="bulletIndent1">However, a factor VIII fusion protein that prevents factor VIII binding to native VWF resulted in similar platelet accumulation as unmodified recombinant factor VIII in a hemophilia A mouse model [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Efanesoctocog alfa (factor VIII-VWF fusion)'</a>.)</p><p></p><p>The C2 domain of factor VIII [<a href="#rid10">10,11</a>] binds to the D1 and adjacent D3 domains of VWF [<a href="#rid24">24</a>]. VWF can bind factor VIII only when factor VIII has not been cleaved by thrombin [<a href="#rid28">28</a>]. After thrombin cleavage, activated factor VIII (factor VIIIa) is released from VWF and becomes a fully functional, active cofactor in the ongoing generation of thrombin; however, it is also now more susceptible to inactivation [<a href="#rid25">25</a>].</p><p>The clinical importance of VWF binding can be illustrated by the findings in type 2N von Willebrand disease (VWD) and in some <em>F8</em> variants leading to decreased binding to VWF:</p><p class="bulletIndent1"><span class="glyph">●</span>Type 2N VWD, transmitted as an autosomal recessive trait, is characterized by pathogenic variants in the <em>VWF</em> gene within the factor VIII binding domain [<a href="#rid29">29,30</a>]. Affected patients present with low levels of factor VIII (usually &lt;10 percent), because of unimpeded proteolytic cleavage of factor VIII, along with a clinical pattern of bleeding similar to that seen in hemophilia A, rather than the predominance of mucosal bleeding associated with classical VWD. Type 2N VWD, rather than hemophilia A, should be suspected in the following situations [<a href="#rid31">31</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Families in which an autosomal (rather than X-linked) inheritance pattern for factor VIII deficiency is suggested</p><p class="bulletIndent2"><span class="glyph">•</span>Isolated factor VIII deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with a low FVIII level but no likely causative variant found on genetic testing</p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who carry a diagnosis of mild hemophilia but have suboptimal response to factor VIII therapy despite absence of an inhibitor </p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'Stabilization of factor VIII'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with genetic variants in the C1 domain of the factor VIII molecule were found to have normal factor VIII specific activity (the ratio between factor VIII coagulant activity and factor VIII antigen) but reduced binding to VWF, resulting in mild to moderate hemophilia A [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Formation of factor VIIIa</span><span class="headingEndMark"> — </span>On exposure to thrombin or factor Xa, a nonessential cleavage at Arg740 transiently converts the heavy chain into 92 kd fragments. Concurrently, cleavage at Arg372 converts the heavy chain into 54 kd and 44 kd fragments. At the same time, a small fragment is cleaved from the light chain to separate factor VIII from VWF [<a href="#rid28">28</a>]. These cleavages produce the activated factor VIII heterotrimer factor VIIIa, which is composed of the 54 kd and 44 kd heavy chain fragments and the 72 kd light chain fragment.</p><p class="headingAnchor" id="H10"><span class="h2">Intrinsic pathway X-ase</span><span class="headingEndMark"> — </span>The physiologic role of factor VIII is to accelerate the cleavage of factor X by factor IXa; the binding sites for factor IXa are in the A2 and A3 domains [<a href="#rid14">14-18</a>]. As noted above, the intrinsic X-ase complex consists of factor IX; the protease; factor X; the substrate; and the cofactors, factor VIIIa, calcium, and phospholipids [<a href="#rid4">4,33</a>]. It has been proposed that factor VIIIa has a stabilizing action that forces the catalytic modules factor IXa and factor X together, markedly accelerating the velocity of the X-ase complex [<a href="#rid34">34</a>]. In addition, the enzyme and the substrate are concentrated on a phospholipid surface of activated platelets or endothelial cells, decreasing the Km by several orders of magnitude.</p><p>Factor VIII cannot become part of the X-ase complex until it is released from VWF, because interaction with VWF inhibits its binding to phospholipid surfaces. The separation from VWF requires the cleavage of the factor VIII light chain by thrombin or factor Xa.</p><p>Although the generation or exposure of tissue factor at the wound site is the primary physiologic event in initiating clotting via the extrinsic pathway, the intrinsic pathway X-ase also is required for normal hemostasis, as illustrated by the bleeding disorders hemophilia A and B. The importance of the intrinsic pathway reflects the limited amount of tissue factor generated in vivo and the presence of tissue factor pathway inhibitor which, when complexed with factor Xa, inhibits the tissue factor/factor VIIa complex [<a href="#rid35">35</a>]. Thus, sustained generation of thrombin depends upon the activation of both factor IX and factor VIII. This process is amplified because factor VIII is activated by both factor Xa and thrombin [<a href="#rid3">3,4</a>] and factor IX is activated by thrombin-induced activation of factor XI [<a href="#rid36">36-38</a>]; as a result, there is a progressive increase in activation of factors VIII and IX as factor Xa and thrombin are formed [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Inactivation of factor VIIIa</span><span class="headingEndMark"> — </span>Factor VIIIa is an unstable molecule that rapidly loses its cofactor function, in part because it is no longer bound to VWF [<a href="#rid24">24,25</a>]. The inactivation of factor VIIIa occurs by subunit dissociation in a process that is initiated by the formation of thrombin. The binding of thrombin to thrombomodulin induces a conformational change in thrombin such that it acquires the ability to activate protein C and no longer promotes platelet activation or the cleavage of fibrinogen (see  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Activated protein C and protein S'</a>). Activated protein C (APC) proteolytically inactivates factors VIIIa and Va, thereby inactivating the intrinsic X-ase and prothrombinase, respectively [<a href="#rid39">39,40</a>]. Factor VIIIa is first cleaved at Arg336 within the A1 subunit and then Arg562, bisecting the A2 subunit [<a href="#rid40">40</a>].</p><p>The rate of APC-mediated inactivation of factor VIIIa is increased several fold by protein S, in concert with APC-inactivated factor V [<a href="#rid41">41</a>], which facilitates cleavage of the A2 subunit; this latter effect is impaired by factor IXa [<a href="#rid40">40</a>]. APC has only a limited effect on non-activated factor VIII, which is protected from catabolism by binding to von Willebrand factor [<a href="#rid23">23-25</a>]. The A2 and A3 domains interact with a macrophage receptor low-density lipoprotein receptor-related protein, enabling these fragments to be removed from the circulation [<a href="#rid42">42</a>]. The sinusoidal endothelial receptor CLEC4M has also been implicated in VWF-independent factor VIII clearance [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H4804261"><span class="h2">Elevated levels of factor VIII</span><span class="headingEndMark"> — </span>Elevated plasma factor VIII coagulant activity is now accepted as an independent marker of increased thrombotic risk. This subject is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Factor VIII'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">FACTOR IX</span><span class="headingEndMark"> — </span>The <em>F9</em> gene is located near the terminus of the long arm of the X chromosome. The gene codes for a signal peptide, a propeptide (promoter region), and the mature 415 amino acid protein that circulates in the plasma (<a class="graphic graphic_figure graphicRef120088" href="/z/d/graphic/120088.html" rel="external">figure 3</a>). Vitamin K-dependent gamma-carboxylation of specific glutamic acid residues occurs as a posttranslational process in the endoplasmic reticulum of the hepatocyte. The propeptide participates in defining a recognition site that designates an adjacent glutamic acid-rich domain for gamma-carboxylation [<a href="#rid44">44</a>]. The amino acids of this recognition site bind directly to the vitamin K-dependent carboxylase [<a href="#rid45">45</a>]; disruption of this site leads to deficient or absent gamma-carboxylation [<a href="#rid44">44</a>]. The processing steps, through which the signal peptide and the propeptide are removed, occur in the Golgi apparatus prior to secretion.</p><p class="headingAnchor" id="H13"><span class="h2">Structure and function</span><span class="headingEndMark"> — </span>Factor IX is a two-chain, disulfide-linked molecule, composed of a light chain (MW 18,000) and a heavy chain (MW 28,000). The N-terminal light chain consists of a gamma-carboxyglutamic acid domain containing 12 gamma-carboxyglutamic acid (Gla) residues dependent upon the vitamin K carboxylase system, followed by a short hydrophobic stack domain that is not required for activation, two epidermal growth factor (EGF)-like domains, and the activation peptide and its flanking sequences [<a href="#rid34">34,46-48</a>].</p><p>Gla confers calcium-binding properties on the vitamin K-dependent proteins. The addition of calcium causes factor IX to undergo a structural transition that leads to exposure of a phospholipid binding site [<a href="#rid49">49-51</a>]. The calcium-stabilized form of factor IX binds to membranes, whereas the magnesium-stabilized form does not [<a href="#rid51">51</a>].</p><p>The EGF-like domains share homology with protein C and factor X, and they may function as binding sites for platelet flanking sequences. A calcium-binding region in the EGF-like domains appears to mediate protein-protein interactions [<a href="#rid52">52</a>].</p><p>The first EGF-like domain is required for activation by tissue factor/factor VIIa but is not essential for activation by factor XIa or for phospholipid binding [<a href="#rid53">53</a>]. The second EGF-like domain is required for the formation of the intrinsic pathway X-ase on the surface of activated platelets [<a href="#rid54">54</a>]. However, the residues responsible for binding to activated platelets are different from those that mediate formation of the X-ase [<a href="#rid55">55</a>].</p><p>The physiologic importance of the EGF-like domains in factor IX function is illustrated by the following observations in humans:</p><p class="bulletIndent1"><span class="glyph">●</span>Deletion of the first EGF-like domain leads to severe hemophilia B [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenic variants in the second EGF-like domain also are associated with hemophilia B; one such variant is associated with a 50-fold reduction in activation by factor XIa (compared to wild-type factor IX), a 20-fold reduction in activation by the tissue factor/factor VIIa complex, and a 14-fold reduction in activation of factor X [<a href="#rid57">57</a>].</p><p></p><p>The N-terminal also contains the site for binding of factor IX to the endothelium, which appears to be mediated through collagen IV [<a href="#rid58">58</a>]. </p><p>The C-terminal heavy chain comprises the catalytic domain of factor IXa. This domain possesses a trypsin-like serine protease fold consisting of two interconnected domains with the catalytic residues His221, Asp269, and Ser365 found at the interface of the two domains [<a href="#rid34">34</a>]. In addition, numerous surface loops exist, connecting the secondary structure elements.</p><p>The serine protease recognizes specific cleavage sites within factor X and is also a target of protease inhibitors, which play an important role in the inactivation of the enzyme. The variable surface loops bordering the substrate binding groove contribute to the specific interaction with both inhibitors and substrates [<a href="#rid59">59-61</a>]. Factor VIIIa has a stabilizing action that forces the catalytic modules factor IXa and factor X together, markedly accelerating the velocity of the X-ase complex [<a href="#rid34">34</a>] (see <a class="local">'Intrinsic pathway X-ase'</a> above).</p><p class="headingAnchor" id="H14"><span class="h2">Activation</span><span class="headingEndMark"> — </span>Factor IX, like factor VIII, is a zymogen that must be activated to factor IXa to participate in coagulation (<a class="graphic graphic_figure graphicRef120088" href="/z/d/graphic/120088.html" rel="external">figure 3</a>). Activation occurs in two ways:</p><p class="bulletIndent1"><span class="glyph">●</span>By the tissue factor/factor VIIa complex of the extrinsic pathway X-ase [<a href="#rid62">62-64</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By factor XIa [<a href="#rid38">38,65</a>], which is formed during activation of the intrinsic coagulation pathway (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>), or by thrombin [<a href="#rid36">36,37</a>]</p><p></p><p>Factor IX is activated by cleavage of peptide bonds Arg145-Ala146 and Arg180-Val 181, resulting in cleavage of the activation peptide [<a href="#rid66">66</a>]. As noted above, factor IXa is the active protease in the intrinsic pathway X-ase, with factor VIIIa, calcium, and phospholipids as cofactors [<a href="#rid4">4,33</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Inactivation of factor IXa</span><span class="headingEndMark"> — </span>Factor IXa is inactivated slowly by antithrombin, a serpin that forms a stable equimolar complex at the Asp359 substrate binding pocket [<a href="#rid67">67</a>]. AT also neutralizes thrombin and factors Xa, XIa, and XIIa.</p><p class="headingAnchor" id="H16"><span class="h1">NATURALLY-OCCURRING GAIN-OF-FUNCTION VARIANTS</span><span class="headingEndMark"> — </span>Naturally-occurring variants in the <em>F8</em> and <em>F9</em> genes have been reported that increase circulation factor levels and/or activity. </p><p>These variants may cause inherited thrombophilia, although the prevalence and relative risk of thrombosis compared with other thrombophilias is unknown, and testing for these conditions is not performed routinely. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Elevated clotting factors and chemokines'</a>.)</p><p class="headingAnchor" id="H3957957741"><span class="h2">Factor VIII Padua</span><span class="headingEndMark"> — </span>A case of inherited thrombophilia associated with a gain-of-function variant in the <em>F8</em> gene (tandem duplication of the promoter, exon 1, and most of intron 1) was reported in 2021 [<a href="#rid68">68</a>]. The proband and related relatives had multiple deep vein thromboses and a factor VIII activity (and antigen) levels &gt;400 percent. Screening of 50 unrelated VTE patients with very high factor VIII levels identified a second pedigree with the identical <em>F8</em> variant, suggesting a founder effect.</p><p class="headingAnchor" id="H2800250094"><span class="h2">Factor IX Padua</span><span class="headingEndMark"> — </span>A case of inherited thrombophilia associated with a gain-of-function variant in the <em>F9</em> gene (<em>F9</em>-R338L, factor IX Padua) was reported in 2009 [<a href="#rid69">69</a>]. The plasma level of the factor IX was normal, but the clotting activity was approximately 8 times normal due to a faster rate of factor X activation [<a href="#rid70">70</a>]. </p><p>This variant is being used in <em>F9</em> gene therapy constructs as a means of increasing the levels of circulating factor IX activity relative to wild-type <em>F9 </em>and the viral vector, potentially increasing efficacy and reducing vector-related toxicity. (See  <a class="medical medical_review" href="/z/d/html/134290.html" rel="external">"Gene therapy and other investigational approaches for hemophilia"</a>.)</p><p class="headingAnchor" id="H8177631"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role in coagulation cascade</strong> – Factors VIII and IX are major components in the generation of the intrinsic pathway X-ase (ten-ase) complex, which, in activated forms (ie, factors VIIIa and IXa) in conjunction with calcium and phospholipids, convert factor X to activated factor X (ie, factor Xa). Factors VIIIa and IXa are responsible for amplification of the coagulation cascade after initial thrombin generation through the extrinsic pathway (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>). (See <a class="local">'Intrinsic pathway X-ase'</a> above and  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Clotting cascade and propagation of the clot'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor VIII</strong> – The <em>F8</em> gene is located on the X chromosome. It is one of the largest known genes, divided into 26 exons that span 186,000 base pairs. Pathogenic variants in the <em>F8</em> gene are responsible for the sex-linked bleeding disorder hemophilia A. (See <a class="local">'Factor VIII'</a> above and  <a class="medical medical_review" href="/z/d/html/1311.html" rel="external">"Genetics of hemophilia A and B", section on 'F8 gene (hemophilia A)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor VIII circulates in plasma in a noncovalent complex with von Willebrand factor (<a class="graphic graphic_figure graphicRef120087" href="/z/d/graphic/120087.html" rel="external">figure 2</a>). (See <a class="local">'Binding to von Willebrand factor'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cleavage of plasma factor VIII by thrombin or factor Xa is necessary to activate factor VIII and allow it to participate in the intrinsic pathway X-ase complex. Activated factor VIII is inactivated by activated protein C in conjunction with protein S. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor IX</strong> – The <em>F9</em> gene is also located on the X chromosome. Pathogenic variants of this gene are responsible for the sex-linked bleeding disorder hemophilia B. (See <a class="local">'Factor IX'</a> above and  <a class="medical medical_review" href="/z/d/html/1311.html" rel="external">"Genetics of hemophilia A and B", section on 'F9 gene (hemophilia B)'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor IX contains 12 gamma-carboxyglutamic acid (Gla) residues dependent upon the vitamin K carboxylase system. Gla confers calcium-binding properties on the vitamin K-dependent proteins, which allows factor IX to bind to phospholipids. (See  <a class="medical medical_review" href="/z/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor IX must be activated to factor IXa to participate in coagulation (<a class="graphic graphic_figure graphicRef120088" href="/z/d/graphic/120088.html" rel="external">figure 3</a>). Activation occurs via the tissue factor/factor VIIa complex of the extrinsic X-ase pathway as well as by factor XIa. Factor IXa is inactivated slowly by antithrombin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gain-of-function variants</strong> – Naturally-occurring gain-of-function variants in the genes for factors VIII and IX have been described. The <em>F9</em> variant is being used in gene therapy constructs for hemophilia B. (See <a class="local">'Naturally-occurring gain-of-function variants'</a> above.)</p><p></p><p class="headingAnchor" id="H1659880145"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge W Keith Hoots, MD, and Amy D Shapiro, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326.</a></li><li><a class="nounderline abstract_t">Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342.</a></li><li><a class="nounderline abstract_t">Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A 1988; 85:2429.</a></li><li><a class="nounderline abstract_t">Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272:21527.</a></li><li><a class="nounderline abstract_t">Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978.</a></li><li><a class="nounderline abstract_t">Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86:1811.</a></li><li><a class="nounderline abstract_t">Saenko EL, Ananyeva NM, Tuddenham EG, Kemball-Cook G. Factor VIII - novel insights into form and function. Br J Haematol 2002; 119:323.</a></li><li><a class="nounderline abstract_t">Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111:1240.</a></li><li><a class="nounderline abstract_t">Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92:3701.</a></li><li><a class="nounderline abstract_t">Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402:439.</a></li><li><a class="nounderline abstract_t">Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269:11601.</a></li><li><a class="nounderline abstract_t">Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274:31000.</a></li><li><a class="nounderline abstract_t">Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275:25774.</a></li><li><a class="nounderline abstract_t">Zhong D, Saenko EL, Shima M, et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92:136.</a></li><li><a class="nounderline abstract_t">Amano K, Sarkar R, Pemberton S, et al. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91:538.</a></li><li><a class="nounderline abstract_t">Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269:20522.</a></li><li><a class="nounderline abstract_t">O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995; 270:27087.</a></li><li><a class="nounderline abstract_t">Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J Biol Chem 1992; 267:3725.</a></li><li><a class="nounderline abstract_t">Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78:256.</a></li><li><a class="nounderline abstract_t">Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15:1187.</a></li><li><a class="nounderline abstract_t">Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014; 123:3697.</a></li><li><a class="nounderline abstract_t">Fahs SA, Hille MT, Shi Q, et al. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014; 123:3706.</a></li><li><a class="nounderline abstract_t">Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.</a></li><li><a class="nounderline abstract_t">Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87:2292.</a></li><li><a class="nounderline abstract_t">Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236.</a></li><li><a class="nounderline abstract_t">Pipe SW, Montgomery RR, Pratt KP, et al. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood 2016; 128:2007.</a></li><li><a class="nounderline abstract_t">Demers M, Aleman MM, Kistanova E, et al. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII. J Thromb Haemost 2022; 20:1674.</a></li><li><a class="nounderline abstract_t">Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263:10451.</a></li><li><a class="nounderline abstract_t">Tuley EA, Gaucher C, Jorieux S, et al. Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A 1991; 88:6377.</a></li><li><a class="nounderline abstract_t">Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost 1997; 78:451.</a></li><li><a class="nounderline abstract_t">Seidizadeh O, Peyvandi F, Mannucci PM. Von Willebrand disease type 2N: An update. J Thromb Haemost 2021; 19:909.</a></li><li><a class="nounderline abstract_t">Jacquemin M, Lavend'homme R, Benhida A, et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96:958.</a></li><li><a class="nounderline abstract_t">Jesty J, Spencer AK, Nemerson Y. The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X. J Biol Chem 1974; 249:5614.</a></li><li><a class="nounderline abstract_t">Brandstetter H, Bauer M, Huber R, et al. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 1995; 92:9796.</a></li><li><a class="nounderline abstract_t">Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46:103.</a></li><li><a class="nounderline abstract_t">Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.</a></li><li><a class="nounderline abstract_t">von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035.</a></li><li><a class="nounderline abstract_t">Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271:29023.</a></li><li><a class="nounderline abstract_t">Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63:486.</a></li><li><a class="nounderline abstract_t">O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000; 95:1714.</a></li><li><a class="nounderline abstract_t">Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999; 25:273.</a></li><li><a class="nounderline abstract_t">Lenting PJ, VAN Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5:1353.</a></li><li><a class="nounderline abstract_t">Swystun LL, Notley C, Georgescu I, et al. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner. J Thromb Haemost 2019; 17:681.</a></li><li><a class="nounderline abstract_t">Jorgensen MJ, Cantor AB, Furie BC, et al. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48:185.</a></li><li><a class="nounderline abstract_t">Hubbard BR, Ulrich MM, Jacobs M, et al. Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site. Proc Natl Acad Sci U S A 1989; 86:6893.</a></li><li><a class="nounderline abstract_t">Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53:505.</a></li><li><a class="nounderline abstract_t">Hughes PE, Handford PA, Austen DE, Brownlee GG. Protein engineering of the hydrophobic domain of human factor IX. Protein Eng 1994; 7:1121.</a></li><li><a class="nounderline abstract_t">Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78:1637.</a></li><li><a class="nounderline abstract_t">Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34:12126.</a></li><li><a class="nounderline abstract_t">Li L, Darden TA, Freedman SJ, et al. Refinement of the NMR solution structure of the gamma-carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca2+ positions determined by a genetic algorithm. Biochemistry 1997; 36:2132.</a></li><li><a class="nounderline abstract_t">Freedman SJ, Blostein MD, Baleja JD, et al. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271:16227.</a></li><li><a class="nounderline abstract_t">Rao Z, Handford P, Mayhew M, et al. The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 1995; 82:131.</a></li><li><a class="nounderline abstract_t">Zhong D, Smith KJ, Birktoft JJ, Bajaj SP. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci U S A 1994; 91:3574.</a></li><li><a class="nounderline abstract_t">Wong MY, Gurr JA, Walsh PN. The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex. Biochemistry 1999; 38:8948.</a></li><li><a class="nounderline abstract_t">Ahmad SS, Wong MY, Rawala R, et al. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Biochemistry 1998; 37:1671.</a></li><li><a class="nounderline abstract_t">Vidaud M, Chabret C, Gazengel C, et al. A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B. Blood 1986; 68:961.</a></li><li><a class="nounderline abstract_t">Hertzberg MS, Facey SL, Hogg PJ. An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa. Blood 1999; 94:156.</a></li><li><a class="nounderline abstract_t">Cheung WF, van den Born J, Kühn K, et al. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A 1996; 93:11068.</a></li><li><a class="nounderline abstract_t">Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Thromb Haemost 1997; 78:501.</a></li><li><a class="nounderline abstract_t">Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997; 272:29987.</a></li><li><a class="nounderline abstract_t">Kolkman JA, Christophe OD, Lenting PJ, Mertens K. Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction. J Biol Chem 1999; 274:29087.</a></li><li><a class="nounderline abstract_t">Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74:5260.</a></li><li><a class="nounderline abstract_t">Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63:1338.</a></li><li><a class="nounderline abstract_t">Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363.</a></li><li><a class="nounderline abstract_t">Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61:1528.</a></li><li><a class="nounderline abstract_t">Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76:1.</a></li><li><a class="nounderline abstract_t">Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.</a></li><li><a class="nounderline abstract_t">Simioni P, Cagnin S, Sartorello F, et al. Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. Blood 2021; 137:2383.</a></li><li><a class="nounderline abstract_t">Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361:1671.</a></li><li><a class="nounderline abstract_t">Lin CN, Kao CY, Miao CH, et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 2010; 8:1773.</a></li></ol></div><div id="topicVersionRevision">Topic 1316 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6438525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Characterization of the human factor VIII gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6438528" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular cloning of a cDNA encoding human antihaemophilic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3128786" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261172" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498393" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7544643" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406064" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Factor VIII - novel insights into form and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965321" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The tertiary structure and domain organization of coagulation factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808564" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586887" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Structure of the C2 domain of human factor VIII at 1.5 A resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7512568" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A role for the C2 domain of factor VIII in binding to von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10521497" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Role of factor VIII C2 domain in factor VIII binding to factor Xa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831589" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639509" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Some human inhibitor antibodies interfere with factor VIII binding to factor IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427707" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8051150" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7592960" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Localization of factor IXa and factor VIIIa interactive sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740424" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198162" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Second generation, B-domain deleted recombinant factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473417" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Functional roles of the factor VIII B domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719406" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Murine coagulation factor VIII is synthesized in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705491" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3936044" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630390" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971673" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27587878" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35466511" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134349" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association of the factor VIII light chain with von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906179" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198195" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33497541" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Von Willebrand disease type 2N: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910910" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4416355" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7568220" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598447" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tissue factor pathway inhibitor and the revised theory of coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019570" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579397" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8910554" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Identification of a factor IX binding site on the third apple domain of activated factor XI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6419799" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688829" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443959" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17425686" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clearance mechanisms of von Willebrand factor and factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30740857" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3802193" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2780546" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3286010" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The molecular basis of blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7831283" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Protein engineering of the hydrophobic domain of human factor IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1912552" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7547952" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9047312" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Refinement of the NMR solution structure of the gamma-carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca2+ positions determined by a genetic algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8663165" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7606779" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170949" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10413468" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484238" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2875754" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381508" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855310" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Identification of the endothelial cell binding site for factor IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198204" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9374470" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506162" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/271951" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6722352" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1931959" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The coagulation cascade: initiation, maintenance, and regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/659613" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Activation of human factor IX (Christmas factor).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194585" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Surface-dependent reactions of the vitamin K-dependent enzyme complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205009" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Antithrombin and its inherited deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33275657" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846852" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : X-linked thrombophilia with a mutant factor IX (factor IX Padua).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492477" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
